NewsBenzingaOculis、急性MS再発におけるPrivosegtorのFDA IND承認を取得 ― 視神経炎および歩行可能な再発を含み、主要評価項目は最短3か月で設定 Oculis、急性MS再発におけるPrivosegtorのFDA IND承認を取得 ― 視神経炎および歩行可能な再発を含み、主要評価項目は最短3か月で設定 Benzinga 2026.11.16 07:07 (GMT+0) Open on Benzinga Other news AECOM Hikes Dividend, Backlog Hits Record $28 Billion Elon Musk Steps in After Jensen Huang Loses X Verification Following Nvidia Exit: ‘Blue Check Coming Back for Free on the House’ Trump Backs Howard Lutnick Amid Nvidia Row, Says Restrictions Could Have Triggered China Showdown: ‘I Understand Both Sides of It’ Nvidia Forms Board Panel for Export-Control Oversight Musk Responds to Jensen Huang's X Account Losing Blue Checkmark and Nvidia Affiliate Badge: Will Restore Blue Check for Free Amazon Cranks Up Its India Clean Energy Investment With Fresh $7 Billion Bet
Elon Musk Steps in After Jensen Huang Loses X Verification Following Nvidia Exit: ‘Blue Check Coming Back for Free on the House’
Trump Backs Howard Lutnick Amid Nvidia Row, Says Restrictions Could Have Triggered China Showdown: ‘I Understand Both Sides of It’
Musk Responds to Jensen Huang's X Account Losing Blue Checkmark and Nvidia Affiliate Badge: Will Restore Blue Check for Free